Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.
,A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is ...
The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...
“ (Weight loss medications) can help, for sure, but exercise and getting enough protein to make sure you aren’t losing muscle ...
Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...
The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...
The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling ...
Eli Lilly (NYSE:LLY) has partnered with the British government to launch a first-of-its-kind real-world study to evaluate the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback